Research programme: chimeric antigen receptor T cell therapy - Abintus Bio
Latest Information Update: 28 Nov 2021
At a glance
- Originator Abintus Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Nov 2021 Abintus Bio in-licenses next generation signaling 1XX technology from Memorial Sloan Kettering Cancer Centre for Solid tumours and Haematologic malignancies
- 17 Nov 2021 Abintus Bio plans a clinical trial for Solid tumours and Haematologic malignancies in early 2023
- 22 Apr 2021 Preclinical trials in Cancer in USA (Parenteral)